"Vicebio secures $100m to advance RSV and hMPV vaccine combo to Phase I" was originally created and published by ...

The respiratory syncytial virus (RSV) space may have filled up over the past year, but that isn’t deterring Vicebio or its ...

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

Vicebio Ltd ("Vicebio"), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, today announces a $100 million Series B financing led by TCGX with ...

The series B fundraising will support the clinical development of next-generation multivalent vaccines against respiratory ...

Vicebio has secured $100mn in Series B funding to further develop its vaccines for multiple respiratory infections.

The company said it is “very confident in Arexvy, which has a best-in class profile, including the highest efficacy (94 per ...

The trial investigated the efficacy and safety of a once-daily 10-mg, 20-mg, and 50-mg dose of monlunabant vs. placebo on body weight after 16 weeks in 243 people with obesity and metabolic syndrome.

You.com, an AI-powered productivity engine, today announced a partnership with Wort & Bild Verlag, Germany's leading health media provider. This collaboration aims to enhance access to health ...

CorriXR Therapeutics, Inc. ("CorriXR"), a biotherapeutics company developing unique genetic medicines that optimize the effectiveness of existing cancer treatments by knocking out genes responsible ...

But lurking in the shadows is a more sinister threat: respiratory syncytial virus, or RSV. Cases begin to rise in September and is at its worst during the winter. Often dismissed as just another ...

In Singapore’s humid climate, where respiratory illnesses can spread year-round, respiratory syncytial virus (RSV) is emerging as a stealthy and significant threat. RSV is a highly contagious ...